


# Barriers and future directions of personalized medicine: from the bench to the patients



Friday, October 2<sup>nd</sup>, 2020

## Program

9:15 – 9:30	<b>Introductory session</b>	
	Prof. Dr. Hiddo Lambers Heerspink, University of Groningen	
9:35 – 10:00	<b>Basic science perspective.</b> <i>Novel perspectives on medicinal chemistry in the postgenomic era</i>	
	Prof. Dr. Frank Dekker, University of Groningen	
10:00 – 10:25	<b>Regulators perspective</b>	
	Prof. Dr. Hans Hillege, University of Groningen	
10:25 – 10:35	<b>Break</b>	
10:35 – 11:00	<b>Clinicians perspective.</b> <i>Advanced application of biomarkers to personalize treatment in patients with heart failure</i>	
	Prof. Dr. Adriaan Voors, University of Groningen	
11:00 – 11:25	<b>Patients perspective.</b> <i>Personalized Medicine; a patient's perspective</i>	
	MsC Ties Obers, Diabetesvereniging Nederland	
11:25 – 11:50	<b>Parallel poster session PROMINENT Ph.Ds</b>	
11:50 – 12:05	<b>Break</b>	
12:05 – 12:55	<b>Lawyers perspective</b>	<b>Ethicists perspective</b>
	<i>Precision Medicine/Ethical Problems, Fragmented Solidarity.</i>	<i>Ambiguity: Rough Justice, Wicked Problems, Fragmented Solidarity.</i>
	Prof. Dr. Andre den Exter Erasmus University Rotterdam	Prof. Dr. Leonard Fleck Michigan State University
12:55 – 13:05	<b>Closing remarks</b>	
	Prof. Dr. Hiddo Lambers Heerspink, University of Groningen	



umcg

This event has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 754425.


# Key-note speakers Biographies

**Speaker:** **Frank Dekker**

**Perspective:** Researchers

**Presentation:** *Novel perspectives on medicinal chemistry in the postgenomic era*

Frank Dekker studies pharmacy at Utrecht University (NL). In 2004 his PhD was awarded at the same university based on the defense of the thesis entitled: 'Modulation of protein-protein interaction in signal transduction'. Subsequently, he moved as a postdoctoral researcher to the group of Prof. Herbert Waldmann in the Max Planck institute in Dortmund, Germany. In 2007, he moved to the university of Groningen. In 2012 he was awarded the prestigious research grants, which enabled appointment as associate professor in the department Chemical and Pharmaceutical Biology.



---

**Speaker:** **Hans Hillege**

**Perspective:** Regulators

**Presentation:**

Hans Hillege is a professor in Cardiology and his educational records include Master's degrees in Medicine and Epidemiology and a PhD from the University of Groningen. Currently he is an acting member of the European Committee of Human Medicinal Products (CHMP) on behalf of the Netherlands. The CHMP of the European Medicines Agency (EMA) is responsible for preparing the Agency's opinions on applications submitted for marketing authorisation and on all questions concerning medicinal products for human use. His fields of specialization and research include cardiovascular epidemiology and the impact of extracardiac comorbidities with specific interest in the coexistence of cardiovascular and kidney disease, epidemiological models, clinical trials, evidence based medicine, regulatory science, medical decision-making and health information technology. One of his current interests is on patient preferences and on how to implement patient preferences into regulatory decisions.



---

**Speaker:** **Adriaan Voors**

**Perspective:** Clinicians

**Presentation:** *Advanced application of biomarkers to personalize treatment in patients with heart failure*

Adriaan Voors is Professor of Cardiology and specializes in heart failure. Since July 2003, Professor Voors is currently working as a Cardiologist in the University Medical Centre Groningen, The Netherlands. Professor Voors has been involved as principal investigator/executive/steering committee member of 49 clinical trials on novel therapies in acute and chronic heart failure. Prof. Voors is the co-chair of the 2016 ESC Heart Failure Guidelines. He has co-authored more than 600 peer-reviewed papers, mainly on heart failure.




This event has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 754425.

**Speaker: Ties Obers, MsC**

**Perspective:** Patients

**Presentation:** *Personalized Medicine; a patient's perspective*

Ties Obers is a patient advocate for the Dutch Diabetes Association (DVN). He is a Type 1 Diabetes patient since 2006. After graduation from his MSc in Public Management he has worked for the international T1D fund JDRF and various other patient centered non-profit organizations. Ties Obers is also part of the client council of the UMC Utrecht.



---

**Speaker: Andre den Exter**

**Perspective:** Lawyers

**Presentation:** (Joint title with Leonard Flecker) *Precision Medicine/Ethical Ambiguity: Rough Justice, Wicked Problems, Fragmented Solidarity.*

André den Exter (1966) is an associate professor of health law at Erasmus School of Law, Erasmus University Rotterdam, the Netherlands. He is the holder of a Jean Monnet Chair of European Union Health Law and has held several visiting (associate) professorships in international and European health law, including one at Danylo Medical University Lviv (Ukraine), and another at the National School of Public Health, Universidade Nova de Lisboa (Portugal).



---

**Speaker: Leonard Fleck**

**Perspective:** Ethicists

**Presentation:** *Precision Medicine/Ethical Ambiguity: Rough Justice, Wicked Problems, Fragmented Solidarity.*

Leonard M. Fleck, Ph.D., Acting Director and Professor of Philosophy/Medical Ethics, Center for Ethics, College of Human Medicine, Michigan State University. He is the author of *Just Caring: Health Care Rationing and Democratic Deliberation* (Oxford, 2009), and co-editor of *Fair Resource Allocation and Rationing at the Bedside* (Oxford, 2015). He has 150 refereed articles and book chapters. Currently completing a manuscript *Precision Medicine, Ethical Ambiguity: Rough Justice and Wicked Problems*.



---

## PROMINENT PhD students

---

### Domain 1: Disease Mechanisms

---

- Zaid Elhusseini [z.m.h.elhusseini@rug.nl](mailto:z.m.h.elhusseini@rug.nl)
  - Anna Palmiotti [a.palmiotti@umcg.nl](mailto:a.palmiotti@umcg.nl)
  - Sara Russo [s.russo@rug.nl](mailto:s.russo@rug.nl)
  - Idil Esen [i.esen@umcg.nl](mailto:i.esen@umcg.nl)
  - Vika Telle [v.telle@rug.nl](mailto:v.telle@rug.nl)
  - Noura Faraj [n.faraj@umcg.nl](mailto:n.faraj@umcg.nl)
- 



---

## Domain 2: Drug Development

---

- Angelina Osipyan [a.osipyan@rug.nl](mailto:a.osipyan@rug.nl)
  - Mohammad Faizan Bhat [m.f.bhat@rug.nl](mailto:m.f.bhat@rug.nl)
  - Karla Arévalo Gómez [k.f.arevalo.gomez@umcg.nl](mailto:k.f.arevalo.gomez@umcg.nl)
- 

## Domain 3: Drug Registration and Evaluation

---

- Martina Ambrož [m.ambroz@umcg.nl](mailto:m.ambroz@umcg.nl)
  - Sonia Roldan Muñoz [s.roldan.munoz@umcg.nl](mailto:s.roldan.munoz@umcg.nl)
  - Sajad Emamipour [s.emamipour@umcg.nl](mailto:s.emamipour@umcg.nl)
- 

## Domain 4: Drug Application

---

- Sok Cin Tye [s.c.tye@umcg.nl](mailto:s.c.tye@umcg.nl)
  - Sara Sokooti Oskooei [s.sokooti.oskooei@umcg.nl](mailto:s.sokooti.oskooei@umcg.nl)
  - Mingjie (Frederick) Duan [m.duan@umcg.nl](mailto:m.duan@umcg.nl)
  - Vicente Artola [v.a.artola.arita@umcg.nl](mailto:v.a.artola.arita@umcg.nl)
- 



university of  
 groningen



umcg

This event has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 754425.